Form 4 for LONA LeonaBio, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0002037968-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2025-12-31 | LONA | Renninger Robert | CFO | M - OptEx | $0.00 | +1,236 | 13.2K | +10% | $0 |
| D | 2026-01-05 | 2025-11-18 | LONA | Renninger Robert | CFO | A - Grant | $2.31 | +1,000 | 11.9K | +9% | +$2,310 |
| D | 2026-01-05 | 2026-01-02 | LONA | Renninger Robert | CFO | S - Sale+OE | $6.88 | -297 | 12.9K | -2% | -$2,043 |
| D | 2026-01-05 | 2025-12-31 | LONA | Renninger Robert | CFO | M - OptEx | $0.00 | -1,236 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | M | A | 1,236 | $0.00 | 13,154 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-18 | A | A | 1,000 | $2.31 | 11,918 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 19, 2025 through November 18, 2025. This transaction is also exempt under Rule 16b-3(c). (F2) The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split"). (F3) The Purchase Period ended November 18, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 19, 2025. (F4) In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2025. |
| 3 | Common | Common Stock | 2026-01-02 | S | D | 297 | $6.88 | 12,857 | D | — | — | (F6) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4 | Derivative | Restricted Stock Units | 2025-12-31 | M | D | 1,236 | $0.00 | 0 | D | — · — to — | 1,236 Common Stock | (F7) RSUs convert into common stock on a one-for-one basis. (F8) Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. (F9) On October 1, 2024, the reporting person was granted 3,707 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. |